Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer.

R Hansen1, T Moynihan, P Beatty

  • 1Department of Medicine, Medical College of Wisconsin, Milwaukee.

Urology
|April 1, 1991
PubMed
Summary

Continuous 5-fluorouracil (5-FU) infusion offered palliative benefits for metastatic prostate cancer patients. Some experienced remission or stable disease with manageable side effects, indicating its potential in refractory cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The lower airway microbiome in paediatric health and chronic disease.

Paediatric respiratory reviews·2024
Same author

Incidence of cutaneous T-cell lymphoma in the Republic of Ireland between 1994 and 2019.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Repeated deep-inspiration breath-hold CT scans at planning underestimate the actual motion between breath-holds at treatment for lung cancer and lymphoma patients.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2023
Same author

Changing hand hygiene behaviour might not be that easy.

The Journal of hospital infection·2021
Same author

Dystrophic calcinosis cutis successfully treated with extracorporeal shockwave lithotripsy.

Clinical and experimental dermatology·2021
Same author

Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources.

Revista de gastroenterologia de Mexico (English)·2018

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic prostate cancer often progresses despite standard treatments.
  • Refractory cases require evaluation of alternative therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of continuous 5-fluorouracil (5-FU) infusion in patients with metastatic prostate cancer.
  • To assess the palliative effects of this treatment in symptomatic, refractory disease.

Main Methods:

  • Twenty patients with symptomatic, progressive metastatic prostate cancer received continuous 5-FU infusion (250-300 mg/M2/day) via a central venous catheter.
  • Patients were treated on an ambulatory basis, and outcomes including remission, disease stability, and toxicity were monitored.

Main Results:

Related Experiment Videos

  • Partial remission (10%) and stable disease (45%) were observed, with a mean duration of benefit of six months.
  • Most patients with benefit showed improvement in pain and performance status (ECOG).
  • Common toxicities included stomatitis (30%), hand/foot syndrome (15%), and diarrhea (5%); no significant myelosuppression occurred.

    • Conclusions:

    • Continuous 5-FU infusion demonstrates palliative potential in symptomatic, refractory metastatic prostate cancer.
    • This treatment approach may offer clinical benefit with manageable toxicity for select patients.